Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases |
Ho, Christopher Chee Kong
(Urology Unit, Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre)
Seong, Poh Keat (Urology Unit, Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre) Zainuddin, Zulkifli Md (Urology Unit, Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre) Abdul Manaf, Mohd Rizal (Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre) Parameswaran, Muhilan (Department of Surgery, Universiti Malaya) Razack, Azad H.A. (Department of Surgery, Universiti Malaya) |
1 | Abuzallouf S, Dayes I, Lukka H (2004). Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol, 171, 2122-7. DOI ScienceOn |
2 | Carlin BI, Andriole GL (2000). The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer, 88, 2989-94. DOI |
3 | Chybowski FM, Keller JJ, Bergstralh EJ, JOesterling JE (1991). Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol, 145, 313-8. |
4 | Gleave M, Coupland D, Drachenberg D, et al (1996). Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urolog, 47, 708-12. DOI ScienceOn |
5 | Gomez P, Manoharan M, Kim SS, Soloway MS (2004). Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int, 94, 299-302. DOI ScienceOn |
6 | Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA (2003). Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol, 43, 226-32. DOI ScienceOn |
7 | Heidenreich A, Aus G, Bolla M, et al (2008). EAU guidelines on prostate cancer. Eur Urol, 53, 68-80. DOI ScienceOn |
8 | Hirobe M, Takahashi A, Hisasue S, et al (2007). Bone scanning--who needs it among patients with newly diagnosed prostate cancer? Jpn J Clin Oncol, 37, 788-92. DOI ScienceOn |
9 | Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007). Imaging prostate cancer: A multidisciplinary perspective. Radiology, 243, 28-53. DOI ScienceOn |
10 | Huang CY, Hsu HC, Chang CH, Tseng KF, Fong YC (2006). Prostate Cancer with Bone Metastases: A Clinical Profile. Mid Taiwan J Med, 11, 82-9. |
11 | Kemp PM, Maguire GA, Bird NJ (1997). Which patients with prostatic carcinoma require a staging bone scan? Br J Urol, 79, 611-4. DOI |
12 | Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72. DOI ScienceOn |
13 | Lai MH, Luk WH, Chan JC (2011). Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population. Urol Oncol, 29, 275-9. DOI ScienceOn |
14 | Lee SH, Chung MS, Park KK, et al (2012). Is it suitable to eliminate bone scan for prostate cancer patients with PSA20 ng/mL? World J Urol, 30, 265-9. DOI |
15 | Lee N, Fawaaz R, Olsson CA, et al (2000). Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys, 48, 1443-6. DOI ScienceOn |
16 | Lin K, Szabo Z, Chin BB, Civelek AC (1999). The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med, 24, 579-82. DOI |
17 | Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T, Gholamrezanezhad A (2013). Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Rev Esp Med Nucl Imagen Mol, [Epub ahead of print]. |
18 | Rudoni M, Antonini G, Favr M, et al (1995). The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med, 22, 207-11. DOI |
19 | Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993). The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA, 269, 57-60. DOI ScienceOn |
20 | Rigaud J, Tiguert R, Normand LL, et al (2002). Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol, 168, 1423-6. DOI ScienceOn |
21 | Salonia A, Gallina A, Camerota TC, et al (2006). Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology, 68, 362-6. DOI ScienceOn |
22 | Thompson I, Thrasher JB, Aus G, et al (2007). Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 177, 2106-31. DOI ScienceOn |
23 | Thurairaja R, McFarlane J, Traill Z, Persad R (2004). Stateof-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int, 94, 268-71. DOI ScienceOn |
24 | Wolff JM, Borchers ZH, Wildberger J, Buell U, Jakse G (2000). Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol, 33, 376-81. |
25 | Zaman MU, Fatima N, Sajjad Z (2011). Metastasis on bone scan with low prostate specific antigen (20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian Pac J Cancer Prev, 12, 1529-32. |